In early 2025, the leadership team at a 135-life manufacturing company in St. Louis sat down to review their group health insurance performance.
What they saw wasn’t routine volatility.
It was concentration risk.
Out of 206 total members on the plan, three specialty prescriptions were consuming nearly $35,000 in a single month:
That wasn’t annual spend.
That was one month.
At the time, pharmacy costs were averaging $119 per member per month (PMPM), putting annual RX spend near $294,000.
For a mid-sized manufacturer competing on tight margins, that’s not background noise.
This was a warning sign.
And it triggered a serious leadership conversation:
Is continuing to offer health benefits sustainable?
The worst part, the carrier reporting is flat our lying and telling them that they are well below “The Norm” for a company of their size.
The Real Problem Wasn’t the Drugs. It Was the Structure.
Specialty medications are expensive. That wasn’t new.
What was new was how much margin was embedded in the delivery.
During our quarterly review, the conversation shifted from renewal tactics to structural control.
Before you can fix runaway pharmacy spend, you have to understand where the dollars are actually going.
Here’s what surfaced.
Spread Pricing
The PBM charged the employer one price. The pharmacy was paid a lower price. The difference was retained as margin.
When we requested claim-level reconciliation data, the reporting came back summarized, not granular.
When we asked for deeper, script-level data, we were told we would need to pay for it and sign an NDA.
To review our own plan’s data.
That’s not transparency.
That’s insulation.
Rebate Dependency
Two problems here.
1) Rebates are retrospective.
2) They’re not savings, they’re just evidence you overpaid in the first place.
And in this manufacturer’s case, those rebates were pooled and averaged across multiple employer groups.
Which means their “rebate” had very little correlation to what their employees actually spent.
Specialty Channel Lock-In
Members were being routed into specialty channels with limited sourcing options and opaque pricing.
Alternative procurement strategies weren’t presented.
Net acquisition cost wasn’t visible.
The system rewarded higher prices, not lower net cost.
This wasn’t an employee utilization problem.
It was structural misalignment inside the pharmacy supply chain.
The Strategic Shift
So what did they do next, they didn’t just switch PBMs.
They restructured their health plan.
We evaluated not only pharmacy performance but the underlying funding strategy behind their group health insurance.
The conclusion was clear:
As long as they remained in their prior structure, they were renting a system they couldn’t control.
So they made a strategic decision.
They moved into a self funded health insurance model within a captive structure.
That shift allowed them to:
-
Share risk more efficiently
-
Stabilize volatility
-
Control vendor selection
-
Build a customized supply chain
Instead of being locked into a bundled carrier solution, they gained the ability to choose their own partners.
That included selecting SmithRx, an independent PBM operating on a true lowest-net-cost model.
No spread pricing. No rebate games. Transparent drug-level pricing. Clear dispensing fees.
Control was restored.
Where the Largest Savings Came From
Once transparency existed, new opportunities surfaced.
Specialty sourcing strategies were evaluated.
Manufacturer assistance programs were explored.
And one of the biggest wins came from a manufacturer coupon program.
A drug that had previously been costing approximately $10,000 per month was secured for $15,000 for a four-month supply.
That single strategy alone eliminated nearly $100,000 in annual RX waste.
Not by denying care.
Not by reducing access.
By utilizing tools that were never presented under the prior model.
The Results
In Q3 2025, pharmacy spend averaged:
$119 PMPM across 206 members
In Q4 2025, after restructuring:
$55 PMPM
That’s a 53% reduction in pharmacy spend.
Annualized:
-
2025 pharmacy spend was tracking near $294,000+
-
2026 pharmacy spend will drop to approximately $136,000
More than $150,000 recovered in year one alone, just from pharmacy.
And a 13% reduction in overall health plan spend.
This wasn’t about cutting benefits.
It was about correcting misalignment.
When you control your vendors, you control your economics.
The Number That Should Make You Uncomfortable
Do you know your pharmacy PMPM?
If you don’t know that number, you’re operating in the dark.
If you do know it, and it’s north of $90–$100 PMPM in a 100–250 life group, you likely don’t have a utilization problem.
You probably have a structural one.
Most employers renew their health insurance because it feels safer than changing it.
Very few understand how to structurally lower the cost of care.
And that’s the difference between surviving renewals… and controlling your spend.
That starts with a simple conversation, focused on evaluating your pharmacy structure, vendor alignment, funding model, and the economic design of your health plan.
Because if you’re a plan sponsor, you don’t just manage benefits you carry a fiduciary responsibility to ensure your health plan is operating in the best interest of the company and its employees.
And it’s hard to defend what you haven’t examined.
If you’re unsure whether your current structure is aligned or quietly working against you start by looking at your claims data, this tells the story and next you should be asking for your vendor contracts. If you can’t decipher exactly how the vendor (PBM, TPA or Carrier) is being paid, then you know you have a problem.
If you are unsure where to look, give us a call or schedule some time with us. You can book your strategic assessment here.
Because the goal isn’t just renewing your health insurance.
It’s controlling the economics behind it.